Clinical trial NCT03136848: The Feasibility and Safety of Normothermic ex Vivo Kidney Perfusion
Official title: A Single Centre Study of the Feasibility and Safety of Using Normothermic ex Vivo Machine Perfusion to Store Human Kidneys for Transplantation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kidney Transplantation
Keywords: perfusion
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2017-05-02
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A pilot study of procedural feasibility involving both device and drug (organ perfusate solution).
Primary purpose: OTHER

Brief summary: Kidney transplantation is the treatment of choice for end-stage kidney failure, but access to transplantation is limited by a severe shortage of donor organs. Although the use of kidneys from higher risk deceased donors has increased the availability of organs, these grafts are associated with a greater risk of delayed function, inferior performance, and shorter survival than standard criteria donor kidneys. The current standard of care for kidney graft preservation prior to transplantation is static cold storage. Preliminary results from large animal kidney transplantation studies and a human clinical trial suggest that normothermic machine perfusion of kidneys prior to transplantation may ameliorate the injury sustained by kidney grafts during cold static preservation, allow assessment of organ viability prior to transplantation, and reduce the risk of delayed graft function or non-function. Such a strategy may not only improve the performance of kidneys that are currently considered acceptable for transplantation, but may also facilitate the assessment and utilization of kidneys that are currently not considered for transplantation. This study will examine the feasibility and safety of normothermic ex vivo perfusion of human kidneys prior to transplantation. The study will evaluate kidney function after transplantation using standard clinical parameters. Study participants will be followed for 3 months following transplantation and their outcomes recorded. Feasibility will be measured using the ratio of actual:eligible kidney grafts preserved by normothermic ex vivo perfusion and will also take into account logistical issues with respect to implementation and ease of use of the ex vivo perfusion device. Safety will be assessed by rates of device failure resulting in organ discard, primary graft non-function, delayed graft function, graft failure, and recipient mortality.

Detailed description: Kidney transplantation is the treatment of choice for suitable patients with end-stage renal disease as it results in lower morbidity and mortality rates when compared to dialysis. Unfortunately, the number of patients referred for transplantation has grown more quickly than the number of suitable grafts from deceased donors.

The use of higher risk organs has expanded the donor pool but at a great cost due to the higher probability that higher risk kidneys will never function (primary non-function, PNF), or will have delayed graft function (DGF). The current standard of care for kidney graft preservation prior to transplantation is static cold storage but higher-risk deceased donor kidneys are particularly vulnerable to the effects of cold storage. Preliminary results from large animal kidney transplantation studies and a human clinical trial suggest that normothermic machine perfusion of kidneys prior to transplantation may ameliorate the injury sustained by kidney grafts during cold static preservation, allow assessment of organ viability prior to transplantation, and reduce the risk of delayed graft function or non-function. Such a strategy may not only improve the performance of kidneys that are currently considered acceptable for transplantation, but may also facilitate the assessment and utilization of kidneys that are currently not considered for transplantation.

This study will examine the feasibility and safety of normothermic ex vivo perfusion of human kidneys prior to transplantation. Kidneys will be retrieved in the standard fashion and stored cold during transit. Upon arrival at the study transplant centre, kidneys will begin perfusion with a normothermic near-physiologic, blood-based solution. Perfusion will last 1-10 hours.

The study will evaluate kidney function after transplantation using standard clinical parameters. Study participants (n=25) will be followed for 3 months following transplantation and their outcomes recorded. Feasibility will be measured using the ratio of actual:eligible kidney grafts preserved by normothermic ex vivo perfusion and will also take into account logistical issues with respect to implementation and ease of use of the ex vivo perfusion device. Safety will be assessed by rates of device failure resulting in organ discard, primary graft non-function, delayed graft function, graft failure, and recipient mortality.

Eligibility criteria: Inclusion Criteria (Organ):

* Single kidneys from DBD (donation after brain death) and DCD (donation after cardiac death) donors
* Kidney is subjected to a maximum of 12 hours of cold storage prior to beginning of NEVKP (normothermic ex vivo kidney perfusion)
* Kidney meets parameters that are acceptable for transplantation according to the study transplant centre's current clinical practices.

Exclusion Criteria (Organ):

* Kidneys from living donors
* Kidneys that would be declined for transplantation under the study centre's current clinical practice
* Kidneys with multiple arteries.
* Kidney grafts from donors positive for Hepatitis B surface antigen or Hepatitis C viremia.

Inclusion Criteria (Participants):

• Adult male and female patients (18 years or more), active on the waiting list for kidney transplantation; able to give informed consent.

Exclusion Criteria (Participants):

* Patients with focal segmental glomerulosclerosis (FSGS)
* Patients with a diagnosis of atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, or thrombotic microangiopathy Patients with a calculated Panel Reactive Antibody (cPRA) greater than 95%
* Patients with known allergies to any of the perfusion solution components
* Patients undergoing retransplantation
* Recipients with pre-existing vascular disease posing technical challenges for transplantation
* Recipients with any clinically-relevant positive DSA (donor-specific antibody) identified
* Transplantation of more than one organ (e.g. liver/pancreas and kidney)
* Refusal of informed consent
* Recipients receiving double kidney grafts (i.e. both kidneys from one donor being transplanted into a single recipient)

Primary outcomes:
measure: the ratio of actual / eligible kidney grafts subjected to study intervention.
timeFrame: assessed 3 months after enrollment of final participant, or up to 48 months, whichever is earlier
measure: The rate of kidney discard or graft failure attributable to the study intervention
timeFrame: from date of first actual intervention to date last participant completes the study followup period of 3 months post-intervention
Secondary outcomes:
measure: duration of post-transplant dialysis
timeFrame: 3 months post-kidney transplantation
measure: rate of primary graft non-function compared to historical, case-matched controls
timeFrame: 3 months post-kidney transplantation
measure: Degree of Ischemia-reperfusion injury as assessed by post-reperfusion kidney biopsies
timeFrame: assessed 3 months after enrollment of final participant
measure: Rate of delayed graft function
timeFrame: 3 months post-kidney transplantation
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
Study officials:
affiliation: Surgeon, MOT, UHN
name: Markus Selzner, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mazilescu LI, Urbanellis P, Kim SJ, Goto T, Noguchi Y, Konvalinka A, Reichman TW, Sayed BA, Mucsi I, Lee JY, Robinson LA, Ghanekar A, Selzner M. Normothermic Ex Vivo Kidney Perfusion for Human Kidney Transplantation: First North American Results. Transplantation. 2022 Sep 1;106(9):1852-1859. doi: 10.1097/TP.0000000000004098. Epub 2022 Mar 1.